Figure 6.

Ultracharacterization studies of Gemcitabine, PLGem and GemPo in PANC1 cells. Cells were left (A) untreated, or treated with (B) free Gemcitabine, (C) GemPo or (D) PLGem for 1 day and then processed for TEM analysis. (n) indicates nucleus localization. Full and doted arrows highlight cytosolic and uptake pathways, respectively.

Papa et al. BMC Cancer 2012 12:419   doi:10.1186/1471-2407-12-419
Download authors' original image